Monotherapy with the HIF-2α inhibitor casdatifan achieves meaningful, durable responses linked to HIF-2α biology with manageable safety in the treatment of individuals with clear cell renal cell carcinoma.

Monotherapy with the HIF-2α inhibitor casdatifan achieves meaningful, durable responses linked to HIF-2α biology with manageable safety in the treatment of individuals with clear…

Prime evidenze incoraggianti arrivano dallo studio su pazienti affetti da tumore renale in stadio avanzato, in particolare carcinoma renale a cellule chiare metastatico (ccRCC).…